Engineering
Chemicals
Biotechnology
Amyris
$2.369876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.52 (-18.71%) Today
+$0.10 (4.42%) After Hours
Why Robinhood?
You can buy or sell Amyris and other stocks, options, ETFs, and crypto commission-free!
About
Amyris, Inc. Common Stock, also called Amyris, is an industrial biotechnology company, which engages in the provision of bioscience solutions. Read More It focuses on the research, development, manufacture, and sale of fuels and farnesene-derived products. Its products include cosmetics, flavors and fragrances, performance materials, diesel, jet fuel, and lubricants. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.
CEO
Employees
414
Headquarters
Emeryville, California
Founded
2003
Market Cap
144.84M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.44M
High Today
$2.80
Low Today
$2.23
Open Price
$2.80
Volume
3.85M
52 Week High
$9.29
52 Week Low
$2.17
Collections
Engineering
Chemicals
Biotechnology
Cosmetics
Materials
Health
Retail
US
News
The Motley Fool11h
3 Takeaways From Amyris' Q4 2018 Earnings Report
Just a few short months ago it seemed like synthetic biology pioneer Amyris (NASDAQ:AMRS) was finally on the right path. The company reported surprisingly solid results from its new business model that relied more on licensing and royalty revenue from partners and less on its ability to commercialize products on its own. By early October, shares had delivered a year-to-date gain of nearly 150% and the company was valued at close to $600 million. Then it all came crashing down. Shares have fallen 70% since ...
Yahoo FinanceMar 22
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Amyris, Inc. Investors (AMRS)
LOS ANGELES, March 22, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Amyris, Inc.
The Motley FoolMar 20
Here's Why Amyris Collapsed Today
What happened Shares of Amyris (NASDAQ:AMRS) fell more than 22% today after the business filed a form NT 10-K with the Securities and Exchange Commission. That's the ominous filing code for the "notification of inability to timely file form 10-K," which is the annual report for a business. Believe it or not, this is the seventh consecutive year (!) the synthetic biology pioneer has been unable to submit its annual report to the SEC on time. The explanation given for the delay this year isn't reassuring ma...
Price Paid on Robinhood
52% Lower
Right Now
52 Week Low
$2.17
Average Price Paid
$4.90
52 Week High
$9.29
Earnings
-$1.36
-$0.70
-$0.05
$0.61
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
$0.44 per share
Actual
-$0.76 per share